Modulation of innate immunity in the tumor microenvironment

Cancer Immunology, Immunotherapy

Volumn 65, Issue 10, 2016, Pages 1261-1268

  Gonzalez Gugel, Elena ^a   Saxena, Mansi ^a   Bhardwaj, Nina ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CIMT 2015; Dendritic cell; Immunotherapy; Matrix metalloproteinase 2; NK cell exhaustion; Tim 3

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; GELATINASE A; INTERFERON RECEPTOR; MELANOMA ANTIGEN; PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TUMOR VACCINE; TYPE I INTERFERON RECEPTOR 1; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; IFNAR1 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; STROMA CELL; TH2 CELL; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TRENDS; TUMOR ESCAPE;

ANIMALS; DENDRITIC CELLS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MATRIX METALLOPROTEINASE 2; MELANOMA; RECEPTOR, INTERFERON ALPHA-BETA; TH2 CELLS; TOLL-LIKE RECEPTOR 2; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84976286494     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1859-9     Document Type: Review

References (47)

1. Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J, Kovarik J (2002) Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49(3):159–166
2. Dye DE, Medic S, Ziman M, Coombe DR (2013) Melanoma biomolecules: independently identified but functionally intertwined. Front Oncol 3:252. doi:10.3389/fonc.2013.00252
3. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A (2009) Distinct patterns of matrix metalloproteinase-2 and -9 expression in normal human cell lines. Oncol Rep 21(3):821–826
4. Oviedo-Orta E, Bermudez-Fajardo A, Karanam S, Benbow U, Newby AC (2008) Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 124(1):42–50. doi:10.1111/j.1365-2567.2007.02728.x
5. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A et al (1994) Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 424(6):641–645
6. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58(5):1048–1051
7. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174. doi:10.1038/nrc745
8. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564):2387–2392. doi:10.1126/science.1067100
9. Renaud V, Godefroy E, Larrieu P, Fleury F, Jotereau F, Guilloux Y (2010) Folding of matrix metalloproteinase-2 prevents endogenous generation of MHC class-I restricted epitope. PLoS ONE 5(7):e11894. doi:10.1371/journal.pone.0011894
10. Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y (2005) alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med 202(1):61–72. doi:10.1084/jem.20042138
11. Godefroy E, Manches O, Dreno B, Hochman T, Rolnitzky L, Labarriere N et al (2011) Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell 19(3):333–346. doi:10.1016/j.ccr.2011.01.037
12. Croft M, So T, Duan W, Soroosh P (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229(1):173–191. doi:10.1111/j.1600-065X.2009.00766.x
13. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N et al (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202(9):1213–1223. doi:10.1084/jem.20051135
14. Eisenbarth SC, Piggott DA, Bottomly K (2003) The master regulators of allergic inflammation: dendritic cells in Th2 sensitization. Curr Opin Immunol 15(6):620–626
15. Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N et al (2014) Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. Cell Rep 9(5):1856–1870. doi:10.1016/j.celrep.2014.10.067
16. Colucci F, Caligiuri MA, Di Santo JP (2003) What does it take to make a natural killer? Nat Rev Immunol 3(5):413–425. doi:10.1038/nri1088
17. Jaleco AC, Blom B, Res P, Weijer K, Lanier LL, Phillips JH et al (1997) Fetal liver contains committed NK progenitors, but is not a site for development of CD34 + cells into T cells. J Immunol 159(2):694–702
18. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H et al (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16 + NK-cell subset. Blood 116(19):3865–3874. doi:10.1182/blood-2010-04-282301
19. Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R et al (2012) Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) 90(1):55–66. doi:10.1007/s00109-011-0806-7
20. Hsia JY, Chen JT, Chen CY, Hsu CP, Miaw J, Huang YS et al (2005) Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J 28(5):335–340
21. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H et al (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88(3):577–583
22. McKay K, Moore PC, Smoller BR, Hiatt KM (2011) Association between natural killer cells and regression in melanocytic lesions. Hum Pathol 42(12):1960–1964. doi:10.1016/j.humpath.2011.02.019
23. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97(6):2731–2736. doi:10.1073/pnas.050588297
24. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. doi:10.1126/science.1068440
25. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R et al (2005) Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105(6):2594–2600. doi:10.1182/blood-2004-04-1441
26. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44–49. doi:10.1126/science.1198687
27. Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR (2012) PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol 25(4):329–332. doi:10.1089/vim.2011.0096
28. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F et al (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39(6):733–740. doi:10.1038/ng2035
29. Schafer JL, Li H, Evans TI, Estes JD, Reeves RK (2015) Accumulation of cytotoxic CD16 + NK Cells in simian immunodeficiency virus-infected lymph nodes associated with in situ differentiation and functional anergy. J Virol 89(13):6887–6894. doi:10.1128/JVI.00660-15
30. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M et al (2011) Reduced frequencies of NKp30 + NKp46 +, CD161 +, and NKG2D + NK cells in acute HCV infection may predict viral clearance. J Hepatol 55(2):278–288. doi:10.1016/j.jhep.2010.11.030
31. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N et al (2009) Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 51(3):458–467. doi:10.1016/j.jhep.2009.05.030
32. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R et al (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Investig 121(9):3609–3622. doi:10.1172/JCI45816
33. Jewett A, Tseng HC (2011) Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer 2:443–457
34. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE et al (2012) Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119(24):5758–5768. doi:10.1182/blood-2012-03-415364
35. da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK et al (2014) Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2(5):410–422. doi:10.1158/2326-6066.CIR-13-0171
36. Gallois A, Silva I, Osman I, Bhardwaj N (2014) Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology 3(12):e946365. doi:10.4161/21624011.2014.946365
37. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492–499
38. Yi JS, Cox MA, Zajac AJ (2010) T-cell exhaustion: characteristics, causes and conversion. Immunology 129(4):474–481. doi:10.1111/j.1365-2567.2010.03255.x
39. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A et al (2015) CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517(7534):386–390. doi:10.1038/nature13848
40. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L et al (2014) The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 15(5):431–438. doi:10.1038/ni.2850
41. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Demoulins T et al (2014) Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Investig 124(4):1810–1820. doi:10.1172/JCI65899
42. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J et al (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Investig 104(2):173–180. doi:10.1172/JCI6909
43. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Investig 105(6):R9–R14. doi:10.1172/JCI9051
44. Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K et al (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181(1):776–784
45. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D et al (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104(21):8947–8952. doi:10.1073/pnas.0703395104
46. Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F et al (2015) Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res 3(3):278–287. doi:10.1158/2326-6066.CIR-14-0202
47. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB (2014) Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2(8):720–724. doi:10.1158/2326-6066.CIR-14-0024